Join us   Log in  

PHARMASPIRE - Volume 13, Issue 1, January-March 2021

Pages: 11-14

Date of Publication: 09-Jun-2022

Print Article   Download XML  Download PDF

Chemotherapy-induced central nervous system toxicity and syndromes

Author: Lovekesh Singh , Sangita Biswas , Gouranga Sundar Roy , Shamsher Singh

Category: Pharmaceutics


Chemotherapy is used for the treatment of cancer but major drawback is central nervous system (CNS) toxicity (Hippocampus and cortical toxicity). Cancer patient’s shows less sensitivity and tolerance on the usage of chemotherapy that causes damages in the body mainly it affects the targets (hippocampus and cortical regions) of the CNS. CNS toxicity occurs through microglia activation, apoptotic cell death, neuronal demyelination, and oxidative stress. In this article, we have discussed the chemotherapy-induced cortical toxicity, hippocampus toxicity, and syndromes of the CNS. It causes toxic effect either single drug or combination of more than one drug.

Keywords: Central nervous system syndromes, chemotherapy, cortical toxicity, hippocampus toxicity


1. Bamati N, Raoofi A. Development level and the impact of technological factor on renewable energy production. Renew Energy 2020;151:946-55.

2. Johannesen N, Tørsløv T, Wier L. Are less developed countries more exposed to multinational tax avoidance? Method and evidence from micro-data. World Bank Econ Rev 2020;34:790-809.

3. Zhao H, Alam A, Chen QA, Eusman MP, Eguchi S. The role of microglia in the pathobiology of neuropathic pain development: What do we knew. Br J Anaesth 2017;118:504-16.

4. Li N, Pan J, Liu W, Li Y, Li F, Liu M. MicroRNA-15a-5p serves as a potential biomarker and regulates the viability and apoptosis of hippocampus neuron in children with temporal lobe epilepsy. Diagn Pathol 2020;15:1-7.

5. de Toffol B, Trimble M, Hesdorffer DC, Taylor L, Sachdev P, Clancy M, et al. Pharmacotherapy in patients with epilepsy and psychosis. EpilepsyBehav 2018;88:54-60.

6. Cintrón-García J, Guddati AK. Management of CNS toxicity of chemotherapy and targeted agents. Am J Cancer Res 2020;10:2617.

7. De la Fuente MI, Alderuccio JP, Lossos IS. Central nervous system emergencies in haematological malignancies. Br J Haematol 2020;189:1028-37.

8. Tannoury J, de Mestier L, Hentic O, Ruszniewski P, Créange A, Sobhani I. Contribution of immune-mediated paraneoplastic syndromes to neurological manifestations of neuroendocrine tumours: A retrospective study. Neuroendocrinology 2020;111:123-8.

9. Van Praag H, Schinder A, Christie B. Functional neurogenesis in the adult hippocampus. Nature 2002;415:1030-4.

10. Ren X, Boriero D, Chaiswing L, Bondada S, Clair DK, Butterfield DA. Plausible biochemical mechanisms of chemotherapy-induced cognitive impairment (“chemobrain”), a condition that significantly impairs the quality of life of many cancer survivors. Biochim Biophys Acta 2019;1865:1088-97.

11. Han R, Yang YM, Dietrich J, Luebke A, Pröschel MM, Noble M. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 2008;7:12-0.

12. Koppelmans V, Breteler M, Boogerd W, Seynaeve C, Gundy C, Schagen S. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol 2012;30:1080-6.

13. Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology 2006;15:422-30.

14. Yang M, Kim J, Kim SH, Kim JS, Shin T, Moon C. Temporal profiles of synaptic plasticity-related signals in adult mouse hippocampus with methotrexate treatment. Neural Regen Res 2012;7:1651.

15. Walker AK, Kavelaars A, Heijnen CJ, Dantzer R. Neuroinflammation and comorbidity of pain and depression. Pharmacol Rev 2014;66:80-101.

16. Brahmbhatt H, MacDiarmid J, EnGeneI C; Molecular Delivery Pty Ltd. Bacterially Derived, Intact Minicells for Delivery of Therapeutic Agents to Brain Tumors. U.S. Patent, No. 2017, 9,844,598.

17. Conway BR. The organization and operation of inferior temporal cortex. Ann Rev Vision Sci 2018;4:381-402.

18. Bartynski WS, Zeigler Z, Spearman MP, Lin L, Shadduck RK, Lister J. Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity. Am J Neuroradiol 2001;22:18659.

19. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: Case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091-8.

20. Moskalev A, Chernyagina E, de Magalhães JP, Barardo D, Thoppi H, Shaposhnikov M, et al. Geroprotectors: A new, structured and curated database of current therapeutic interventions in aging and age-related disease. Aging (Albany NY) 2015;7:616.